Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 146 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07245927Recruiting
Staphylokinase for massive pulmonary embolism with shock
This trial tests a single injection of a clot-busting drug called staphylokinase for people with a massive pulmonary embolism that is causing shock or very low blood pressure. It aims to see how well the drug works in this emergency situation.
BelgorodAges 18 years+ - NCT07838298RecruitingPhase 4
Flu vaccine response in older adults who get it yearly
This study checks how well the seasonal flu vaccine works in people 65 and older who have had flu shots regularly. It compares their immune response to that of younger adults to see if repeated vaccination still protects them.
SeoulAges 19 years+ - NCT07783243Recruiting
Leishmaniasis vaccine response study in Ethiopia
This study tests how your immune system responds to parts of a potential vaccine for leishmaniasis. Doctors will take small blood or skin samples to see if your body's cells react to these vaccine pieces, which could help design a better vaccine in the future.
Addis AbabaAges 18–65 - NCT07390474RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
Atlanta, GeorgiaAges 18–55 - NCT07324837RecruitingPhase 3
Study of a clot-busting drug for stroke up to 24 hours later
This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.
Ryazan, Ryazan OblastAges 18 years+ - NCT06362746RecruitingPhase 3
Staphylokinase for intermediate high-risk pulmonary embolism
This trial tests a new drug, staphylokinase, to see if it can break up blood clots in the lungs in people with a moderate-high risk pulmonary embolism. The goal is to improve blood flow and reduce the chance of complications.
Barnaul, Altayskiy KrayAges 18 years+ - NCT03132311RecruitingPhase 4
Yellow fever vaccine study for certain people with HIV
This trial checks whether a yellow fever vaccine is safe and works well in adults with HIV who have relatively healthy immune function. It may help doctors understand the best way to protect people with HIV who have never had this vaccine.
Rio de JaneiroAges 18–59 - NCT03609398RecruitingPhase 2
Phase 2 study of a Rift Valley fever vaccine for safety
This study tests how safe a Rift Valley fever (RVF) vaccine is and how strongly it triggers the body’s immune response. You may be eligible if you are at risk of RVF exposure and your blood test shows you don’t already have strong protection.
Fort Deterick, MarylandAges 18–65 - NCT04875819RecruitingPhase 4
HIV vaccine safety check for meningitis and pneumonia shots
This trial studies how safe and how well the body’s immune system responds to meningococcal and pneumococcal vaccines in adults living with HIV. It may help confirm these vaccines work properly and are safe for people on HIV treatment.
HvidovreAges 18 years+ - NCT05554068RecruitingPhase 2
Testing the shingles vaccine response after bone marrow transplant
This Phase 2 study looks at how well the shingles vaccine works in people who had an allogeneic (donor) stem cell transplant. It aims to measure the body’s immune response to the vaccine and check that it’s safe in this recovery period.
Maywood, IllinoisAges Any age - NCT05823285RecruitingPhase 1
Study of QLS31903 for advanced solid tumors
This Phase 1 trial tests the safety and how the medicine works in the body, and also looks at early signs of effectiveness. It is for adults with advanced solid tumors, and for Phase 1b specifically, the tumor must show a marker called GPC3.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06044077RecruitingPhase 3
Testing a new pneumonia vaccine in healthy people
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
Chengdu, SichuanAges 2 years+ - NCT04446832Recruiting
Vaccine study for people waiting for liver transplant
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
LyonAges 18 years+ - NCT05422508RecruitingPhase 2
Second chickenpox shot for healthy kids after one prior vaccine
This study gives a second chickenpox vaccine dose to healthy children who were vaccinated once before. It mainly checks safety and measures the body’s immune response to see how well the second dose works.
AnsanAges 4–6 - NCT06344065RecruitingPhase 3
New whooping cough combo vaccine for 3-month-old infants
This trial tests a new combination vaccine that protects infants against diphtheria, tetanus, and whooping cough. It is for healthy 3-month-old babies whose parents have not yet given them a similar shot.
Nanning, GuangxiAges 3 months–3 months - NCT04422366RecruitingPhase 3
9-valent HPV vaccine study for healthy Chinese women
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
Liuzhou, GuangxiAges 20–45 - NCT07840027RecruitingPhase 1
Vaccine for early Parkinson's disease
This study tests a new investigational vaccine called TRB-001 for people with early Parkinson's disease. It looks at whether the vaccine is safe and whether it can help the immune system fight the disease.
ViennaAges 40–75 - NCT07833436RecruitingPhase 1
Testing a new Lassa fever vaccine
This trial tests a new vaccine against Lassa fever to see if it is safe and how well it triggers an immune response. It may help protect against this serious infection.
ParisAges 18–55 - NCT07811037RecruitingPhase 1/Phase 2
Safety and effect of SGT003 for advanced solid tumors
This trial tests a new experimental medicine called SGT003 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the medicine is safe, how the body handles it, and whether it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07802964RecruitingPhase 1
Early study of HRS-4139 in healthy adults
This trial studies an investigational medicine called HRS-4139 in healthy adults. The purpose is to see how safe it is, how the body processes it, and how it affects the immune system.
Changsha, HunanAges 18–55 - NCT07794748RecruitingPhase 3
Pneumococcal vaccine study for adults aged 18 to 49
This study tests a new pneumococcal vaccine to see if it is safe and triggers a good immune response. It may help protect you from infections like pneumonia, but you must not have had any pneumococcal vaccine since age 5.
Birmingham, AlabamaAges 18–49 - NCT07789964RecruitingPhase 1
Testing a biosimilar of Taltz in healthy adults
This study tests a biosimilar version of Taltz (SB35) against the original in healthy adults. It checks how the drug is absorbed and if it is safe, without causing serious side effects, helping to ensure the biosimilar works the same way.
Busan, BusanAges 19–55 - NCT07780383RecruitingPhase 1
Single-dose study for healthy adults and early Alzheimer's participants
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
Anaheim, CaliforniaAges 18–80 - NCT07779408RecruitingPhase 1/Phase 2
H5N8 flu vaccine study for healthy adults
This study tests an experimental flu vaccine designed to protect against the H5N8 bird flu virus. It is given with an ingredient that may boost the immune response. The study will check if the vaccine is safe and how well it triggers the body's defenses.
Tempe, ArizonaAges 18 years+
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 146 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.